In addition, combination strategies with PI3K/AKT pathway inhibitors may help mitigate compensatory activation, as seen in GBM models where PI3K inhibitors blocked AKT activation induced by PDE10A suppression (209). The gene discussed is PDE10A; the disease is glioblastoma.